{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=27",
    "query": {
      "condition": "Hematologic",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 10739,
    "total_pages": 1074,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T08:03:11.387Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00504634",
      "title": "Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2004-01",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2011-09-15",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00504634"
    },
    {
      "nct_id": "NCT00008164",
      "title": "Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Langerhans Cell Histiocytosis",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Herbert Irving Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "1997-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00008164"
    },
    {
      "nct_id": "NCT04053699",
      "title": "Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrand Diseases"
      ],
      "interventions": [
        {
          "name": "Von Willebrand Factor-Containing Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "66 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "66 Months and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-06-25",
      "completion_date": "2021-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-12-07",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04053699"
    },
    {
      "nct_id": "NCT00260299",
      "title": "Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mevalonic Aciduria",
        "Mevalonate Kinase Deficiency",
        "Immune System Diseases",
        "Periodic Fever Syndromes, Hereditary",
        "Lipid Metabolism, Inborn Errors"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2005-02",
      "completion_date": "2016-01-31",
      "has_results": false,
      "last_update_posted_date": "2019-05-24",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00260299"
    },
    {
      "nct_id": "NCT02546219",
      "title": "a4b7 Integrin in Eosinophilic Esophagitis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Eosinophil isolation and characterization.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2016-03",
      "completion_date": "2018-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546219"
    },
    {
      "nct_id": "NCT01142232",
      "title": "Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide plus Melphalan during autologous stem cell transplantation",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide maintenance",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Attaya Suvannasankha",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2010-08-27",
      "completion_date": "2019-05-18",
      "has_results": true,
      "last_update_posted_date": "2019-10-22",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01142232"
    },
    {
      "nct_id": "NCT02658487",
      "title": "Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia With Multilineage Dysplasia",
        "Myeloid Sarcoma",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Acute Myeloid Leukemia",
        "Therapy-Related Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Vosaroxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2016-03",
      "completion_date": "2024-09",
      "has_results": true,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Charleston, South Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658487"
    },
    {
      "nct_id": "NCT02184533",
      "title": "Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer",
        "Multiple Myeloma",
        "Plasmacytoma"
      ],
      "interventions": [
        {
          "name": "sodium selenite",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2014-07",
      "completion_date": "2018-05",
      "has_results": false,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184533"
    },
    {
      "nct_id": "NCT02796365",
      "title": "Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Doxorubicin Induced Cardiomyopathy",
        "Breast Cancer",
        "Gastric Cancer",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2016-06",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796365"
    },
    {
      "nct_id": "NCT01962792",
      "title": "Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2013-12",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-10-14T08:03:11.387Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962792"
    }
  ]
}